SWHR provided comments to the Eunice Kennedy Shriver National Institute of Child Health and Human Development following the June 24 public […]
SWHR hosted three value assessment experts at its recent policy meeting to discuss the integration of women’s health priorities into assessments of new health care innovations.
SWHR signed onto a congressional letter of support for H.R. 6383, the Uterine Fibroid Research and Education Act of 2020. […]
SWHR provided feedback on a white paper from Sen. Lamar Alexander, chair of the Senate Health, Education, Labor, and Pensions […]
SWHR joined 25 organizations in urging the Food and Drug Administration (FDA) and National Institutes of Health (NIH) to include […]
SWHR provided the Centers for Disease Control and Prevention (CDC) with requested comments on Management of Acute and Chronic Pain. […]
ICER's updated value assessment framework embraces several of SWHR’s recommendations, but more work remains to adequately evaluate the value of health care interventions for women.
Some of screening and diagnostic tests for women are woefully outdated or nonexistent, resulting in uncertainties about their disease risk and difficulty with diagnosis.
Menstrual products are as essential as toilet paper — and for some women equally as hard to find during the COVID-19 pandemic.
This week, SWHR President and CEO Kathryn G. Schubert, MPP, provided outside witness testimony on behalf of the Society for […]